Chemotherapy-Induced Peripheral Polyneuropathy in Pediatric Acute Lymphoblastic Leukemia: A Case Report on Manifestation, Management, and Outcome

IF 1.9 Q4 ONCOLOGY

Cancer reports Pub Date : 2025-08-20 DOI:10.1002/cnr2.70293

Eman Al Mattar, Sondus Al Sharidah, Omnia A. Hashem

{"title":"Chemotherapy-Induced Peripheral Polyneuropathy in Pediatric Acute Lymphoblastic Leukemia: A Case Report on Manifestation, Management, and Outcome","authors":"Eman Al Mattar, Sondus Al Sharidah, Omnia A. Hashem","doi":"10.1002/cnr2.70293","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Chemotherapy-induced peripheral polyneuropathy (CIPN) is a debilitating side effect of cancer treatment such as in acute lymphoblastic leukemia (ALL). Characterized by the dysfunction of the peripheral nervous system, CIPN can occur in 90% of pediatric patients, significantly impairing their quality of life. In most cases, it necessitates the modification of standard chemotherapy regimens, which can compromise the treatment efficacy and increase the risk of relapse.</p>\n </section>\n \n <section>\n \n <h3> Case</h3>\n \n <p>We report a 16-year-old boy with ALL who developed CIPN during induction therapy. A multidisciplinary, individualized treatment approach combined with regular follow-ups ensured optimal management. The patient achieved complete remission with significant improvement in mobility and neurological functions.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Early recognition and comprehensive management of CIPN in pediatric ALL patients are essential to optimizing outcomes while maintaining the overall efficacy of chemotherapy.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 8","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70293","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70293","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Chemotherapy-induced peripheral polyneuropathy (CIPN) is a debilitating side effect of cancer treatment such as in acute lymphoblastic leukemia (ALL). Characterized by the dysfunction of the peripheral nervous system, CIPN can occur in 90% of pediatric patients, significantly impairing their quality of life. In most cases, it necessitates the modification of standard chemotherapy regimens, which can compromise the treatment efficacy and increase the risk of relapse.

Case

We report a 16-year-old boy with ALL who developed CIPN during induction therapy. A multidisciplinary, individualized treatment approach combined with regular follow-ups ensured optimal management. The patient achieved complete remission with significant improvement in mobility and neurological functions.

Conclusions

Early recognition and comprehensive management of CIPN in pediatric ALL patients are essential to optimizing outcomes while maintaining the overall efficacy of chemotherapy.

Abstract Image

查看原文本刊更多论文

化疗诱导的小儿急性淋巴细胞白血病周围多神经病变：一例表现、治疗和结果报告

化疗引起的周围多神经病变（CIPN）是癌症治疗（如急性淋巴细胞白血病（ALL））的一种衰弱性副作用。CIPN以周围神经系统功能障碍为特征，可发生在90%的儿科患者中，严重影响其生活质量。在大多数情况下，需要修改标准的化疗方案，这可能会损害治疗效果并增加复发的风险。我们报告一个16岁的ALL男孩在诱导治疗期间发生CIPN。多学科、个性化的治疗方法与定期随访相结合，确保了最佳管理。患者获得完全缓解，活动能力和神经功能显著改善。结论儿科ALL患者CIPN的早期识别和综合管理是优化预后和保持化疗总体疗效的关键。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊